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Outpatient HIV Clinic Visits
Clinic Visit 1 (8/16/2021)
HPI: Megan Smith is a 56-year-old African American female referred to Pacific HIV clinic after
having tested HIV-positive at an urgent care 2 days ago. She reports having multiple sex
partners over the past 5 years and denies consistent use of protection during sexual
intercourse. One of her previous sex partner from years ago notified her that she was recently
diagnosed with HIV, thus prompting her to get tested. She denies having any history or s/sxs of
a STIs. Patient is aware of her needing to start ART and is willing to start. However, she wishes
to have a single tablet daily ART regimen and to avoid any injectable medications given she is
already taking many medications at home.
Urgent care labs report:
HIV Ag: detected
HIV Ab: detected
HIV-1/HIV-2 antibody differentiation immunoassay: (+) HIV-1, (-) HIV-2
N. gonorrhoeae NAAT: negative
C. trachomatis NAAT: negative
RPR: negative
PMH: T2DM, hypertension, CKD Stage 3, asthma, PAD
SH: Bisexual, reports being sexually active with multiple sex partners previously but recently
started a relationship with a female partner, denies tobacco or recreational drug use
Home Medications:
Aspirin 81 mg 1 tab PO daily
Atorvastatin 80 mg 1 tab PO daily
Insulin NPH 40 units SC BID
Losartan 100 mg 1 tab PO daily
Hydrochlorothiazide 25 mg 1 tab PO daily
Flovent HFA 44 mcg/actuation 2 puffs INH BID
Proventil 90 mcg/actuation 2 puffs INH q4h PRN SOB
Assessment/Plan: Based on patient’s social history and test, patient is newly diagnosed with
HIV. Will start patient on Biktarvy. Patient was educated on importance of safe sex and other
appropriate measures to decrease transmission of HIV. Patient was also informed to let any
sexual partner in the previous 5-10 years know regarding possible HIV transmission and
encourage testing. Will f/u with patient in 4 weeks to assess treatment.
Prescription Order (sent to Pacific pharmacy):
Biktarvy 1 tab PO daily; Quantity: 30; Refill: 1
Prescription Follow-up
Pharmacy informed that Biktarvy is not covered by patient’s insurance, Pacific Health.
Formulary for single tab regimen for HIV was requested from patient’s insurance and is attached
below. The pharmacy was informed by patient’s insurance that the HIV medications that require
PA are easily approved most of the time. Follow-up with pharmacy to change prescription to
Dovato. Patient was called regarding prescription change.
Pacific Health Insurance Formulary:
Drug

Formulary Status

Atripla (efavirenz/tenofovir DF/emtricitabine)
Symfi (efavirenz/tenofovir DF/lamivudine)
Complera (rilpivirine/tenofovir DF/emtricitabine)
Odsefsey (rilpivirine/tenofovir AF/emtricitabine)
Stribild (elvitegravir/cobicistat/tenofovir DF/emtricitabine)
Genvoya (elvitegravir/cobicistat/tenofovir AF/emtricitabine)
Triumeq (dolutegravir/abacavir/lamivudine)
Biktarvy (bictegravir/tenofovir AF/emtricitabine)
Symtuza (darunavir/cobicistat/tenofovir AF/emtricitabine)
Juluca (dolutegravir/rilpivirine)
Dovato (dolutegravir/lamivudine)

PA required
PA required
PA required
Not covered
PA required
Not covered
PA required
Not covered
PA required
Not covered
PA required

Prescription Order (sent to Pacific pharmacy):
Dovato 1 tab PO daily; Quantity: 30; Refill: 1
Clinic Visit 2 (9/10/2021)
HPI: Megan Smith is a 56 years old African American female who was diagnosed with a HIV-1
infection 1 month ago and was started on Dovato. Patient reports no acute complaint after
starting treatment. She admits missing some doses of Dovato in the last month but claims to be
80% compliant overall. She is more aware to practice safe sex and she is grateful that her
current partner tested negative.
PMH: HIV, T2DM, CKD Stage 3, HTN, asthma, PAD
Home Medications:
Aspirin 81 mg 1 tab PO daily
Atorvastatin 80 mg 1 tab PO daily
Insulin NPH 40 units SC BID
Losartan 100 mg 1 tab PO daily
Hydrochlorothiazide 25 mg 1 tab PO daily
Flovent HFA 44 mcg/actuation 2 puffs INH BID
Proventil 90 mcg/actuation 2 puffs INH q4h PRN SOB
Dovato 1 tab PO daily
Assessment/Plan: CD4+ has increased and viral load has decreased. Continue Dovato.
Patient was educated regarding importance of compliance with HIV medication. Patient wishes
to be seen less due to work schedule. Follow up in 3 months.
Prescription Order (sent to Pacific pharmacy):
Dovato 1 tab PO daily; Quantity: 30; Refill: 3
Clinic Visit 3 (12/13/2021)
HPI: Megan Smith is a 56 years old African American female who has been on Dovato for HIV
treatment. Patient reported improved medication compliance to 95%. She denies any complaint
but has been noticing white plaques around her oral cavity. Patient denies any dysphagia or
pain.
PMH: HIV, T2DM, CKD Stage 3, HTN, asthma, PAD
Home Medications:
Aspirin 81 mg 1 tab PO daily
Atorvastatin 80 mg 1 tab PO daily
Insulin NPH 40 units SC BID

Losartan 100 mg 1 tab PO daily
Hydrochlorothiazide 25 mg 1 tab PO daily
Flovent HFA 44 mcg/actuation 2 puffs INH BID
Proventil 90 mcg/actuation 2 puffs INH q4h PRN SOB
Dovato 1 tab PO daily
Physical Exam:
ENT: White patches on the surface of the oral mucosa and tongue
Assessment/Plan: CD4+ count and viral load continues to improve. Oral candidiasis detected.
Continue Dovato and initiate antifungal therapy. Follow-up in 3 months and patient was
informed to contact clinic if candidiasis does not resolved or worsened.
Prescription Order (sent to Pacific pharmacy):
Dovato 1 tab PO daily; Quantity: 30; Refill: 3
Fluconazole 100 mg 1 tab PO daily; Quantity: 7; Refill: 0
Missed Appointment Note
Patient did not come to clinic appointment today. Tried contacting by phone but the number was
busy and voicemail inbox was full. No message was left. Will call back next week.
____________________________________________________________________________
Phone Call Follow-up
Patient was contacted again to follow-up and call wasn’t being picked up. No message was left
due to full voicemail inbox. No message was left. Will send correspondent note via mail.

Admission Day 1 (5/31/2022)
Admission Note
HPI: Megan Smith is a 56 years old female brought in by her partner with fever and confusion.
Her partner mentioned that she started having bad headaches 2 days ago and she tried taking
Advil with only slight relief. Her headache got worsened and she felt chill last night. Today she
called in sick to work and when her partner checked on her after work, she looked very sick and
was confused on what is going on with her. Her partner also reported that the patient had not
been taking her HIV medications since there was no refill left 3 months ago and she had been
too busy with work to follow-up with the clinic.
PMH: HIV-1, T2DM, CKD Stage 3, hypertension, asthma, PAD
Home Medications:
Aspirin 81 mg 1 tab PO daily
Atorvastatin 80 mg 1 tab PO daily
Dovato 1 tab PO daily
Insulin NPH 40 units SC BID
Losartan 100 mg 1 tab PO daily
Hydrochlorothiazide 25 mg 1 tab PO daily
Flovent HFA 44 mcg/actuation 2 puffs INH BID
Proventil 90 mcg/actuation 2 puffs INH q4h PRN SOB
SH: Bisexual, in a relationship with a female partner; denies tobacco or recreational drug use
PE:
Vitals: BP 135/81, T 38.5°C, HR 91 RR 26, O2 sat 98% on RA, Ht 5’5”, Wt 189 lbs
Gen: confused female in acute distress

HEENT: mucosa membranes dry but pink, no tongue trauma
Resp: normal and regular rate, appropriate respiratory excursion
CV: normal rate, regular rhythm, no rubs or gallops, (-) JVD
Abd: normoactive bowel sounds, nontender to light or deep palpation, no organomegaly
Ext: Skin intact with no lesions, peripheral pulses are equal and palpable
Neuro: limited examination due to altered mental status, A&O x1 to person
Assessment/Plan:
1. Encephalopathy 2/2 to possible meningitis, r/o other etiology: STAT lumbar puncture. Initiate
empiric antibiotics and antiviral. Obtain cultures and CT head.
2. HIV: low CD4 count and high viral load compared to previous readings. Obtain genotype
resistance test. Continue current regimen while waiting.
3. Hyperglycemia: continue home regimen and sliding scale as needed
4. CKD Stage 3: renal function at baseline, continue to monitor
CT Head
Indication: Headache
Technique: CT imaging of the head was performed without intravenous contrast
Comparison: None
Findings: No intracranial hemorrhage, mass effect, shift of midline structures, or extra-axial. No
fractures are identified. Visualized paranasal sinuses, mastoid air spaces, and orbits are
unremarkable. Soft tissues of the scalp are within normal limits.
Impression: No intracranial hemorrhage, mass effect, or infarct observed.
Lumbar Puncture
Indication: Encephalopathy
Consent: Consent was obtained from Ms. Shonda (partner) prior to the procedure. Indications,
risks, and benefits were explained at length.
Technique: multiple transverse and longitudinal sonographic images of the left lower extremity
deep venous system with gray-scale, color Doppler, and spectral Doppler flow. Compression
and augmentation maneuvers were performed.
Procedure summary: The patient was placed in the left lateral recumbent position with help from
the nursing staff. The area was cleansed and draped in usual sterile fashion using betadine
scrub. Anesthesia was achieved with 1% lidocaine. A 3.5-inch spinal needle was placed in the
L2-L3 lumbar interspace. On the second attempt, clear, transparent cerebral spinal fluid was
obtained. CSF fluid collected and a sterile band-aid was placed over the puncture site. The
patient had no immediate complications and tolerated the procedure well. Estimated blood loss
was <10 ml.
Findings: Cloudy fluid was obtained. No xanthochromia.
Impression: Meningitis cannot be ruled out from the CSF analysis. Specimens are sent for further
microbiology tests.
ECG
Rate 87, PR 121, QRSD 80, QT 305, QTc 389. No abnormality.

Admission Day 2 (6/1/2022)

Inpatient Progress Note
Impression:
Patient’s mental status is still altered when examined at bedside with RN. RN reports
continuous fever overnight and a hypoglycemic reading this morning. STAT dextrose was
administered and hypoglycemia resolves.
Physical Exam:
General: Awake but not alert, oriented x1 person
HEENT: Normocephalic, atraumatic, no scleral icterus or conjunctival injection
Neck: Supple, no rigidity, no lymphadenopathy
Lungs: Clear to auscultation bilaterally, no crackle or wheezes
CV: RRR, no murmur
GI: soft, nontender, normoactive bowel sounds, no rebound, guarding, or masses
Ext: no ulceration, warm to touch
Neuro: no gross motor deficits, moves all extremities
Plan:
1. Meningitis: CSF fluid analysis positive for Cryptococcus neoformans. Consult ID and
pharmacy for treatment.
2. HIV: Resistance test comes back with multiple mutations. Consult ID and pharmacy for HIV
regimen.
3. Hyperglycemia: hypoglycemic today. Consult pharmacy for insulin dosing.
4. CKD Stage 3: renal function at baseline, continue to monitor
Summary of Work-up
Actual BW: 85.9 kg (BMI 31.4)
IBW: 57 kg
AdjBW: 68.6 kg
Labs:

CBC
WBC (cell/ml)
Hgb (g/dl)
Hct (%)
Plt
BMP
Na (mEq/l)
K (mEq/l)
Cl (mEq/l)
CO2 (mEq/l)
Glu (mg/dl)
BUN (mg/dl)
SCr (mg/dl)
CrCl (use AdjBW)*
Tbili (mg/dl)
ALT (IU/l)
AST (IU/l)
Alkphos (IU/l)
Ca (mg/dl)

Clinic
visit 1
(Aug ’21)

Clinic
visit 2
(Sep ’21)

Clinic
visit 3
(Dec ’21)

Day 1
Admission PM
(May 31 ‘22)

Day 2 AM
(June 1 ’22)

7,000
14.2
41.8
234,000

6,700
13.7
39.8
213,000

6,200
13.9
38.8
225,000

11,200
13.2
38.9
189,000

10,900
13.8
40.2
200,000

141
3.8
99
25
201
40
2.2
30.9
0.9
21
20
72

144
3.7
101
25
186
38
2.1
32.4
1.1
23
35
87

140
3.6
102
23
199
42
2
34
0.8
28
30
85

138
3.5
102
22
189
35
1.9
35.8
1
32
26
68
8.9

134
3.6
100
24
65
37
2
34

Mg (mg/dl)
1.8
1.9
P (mg/dl)
3
Alb (g/dl)
4
A1C (%)
8.8
TC (mg/dL)
197
HDL (mg/dL)
38
LDL (mg/dL)
110
TG (mg/dL)
130
HIV Labs
HIV VL (copies/mL)
97,020
61,500
45,200
156,000
CD4+ count (cells/mm3) 206
305
458
46
CSF Fluid Analysis & Micro
Glucose (mg/dl)
22
Protein (mg/dl)
450
Gross appearance
Cloudy
WBC (cells/uL)
13500
Blood Microbiology
HSV 1 & 2 Ab
Negative
RPR (syphilis)
Non-reactive
Toxoplasma gondii IgG
Detected
SARS-Cov-2 PCR
Negative
HBV surface Ab
Non-reactive
HBV Ag
Negative
HCV Ab
Non-reactive
Blood culture 1
Pending
Blood culture 2
Pending
CSF culture
Pending
Genotypic
HIV
Q148K mutation
resistance test
E138K mutation
*Students need to calculate CrCl and they should know to use adjusted BW if actual BW
is >30% of IBW
Day 2 lab note
CSF Microbiology
E. coli PCR
H. influenza PCR
L. monocytogenes PCR
N. meningitidis PCR
S. agalactiae PCR
VZV PCR
CMV PCR
Enterovirus PCR
Cryptococcus neoformans PCR
Cryptococcus Ab

Results
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Detected
Detected

Vitals

BG POCT

Medications/Orders:
Vancomycin 1000 mg IV q24h
Ceftriaxone 2 g IV q24h
Acyclovir 850 mg IV q8h
Insulin glargine 80 units QHS
Insulin sliding scale TID AC
Vaccine completed: COVID 3 doses, flu, Tdap/Td
Dextrose 10 g x1 (after hypoglycemia reading)
Student Instructions
1. Please provide complete SOAP for the main problems with specific instructions as follows.

•

Cryptococcal meningitis: provide full treatment plans for cryptococcal meningitis,
including acute treatment to resolve infection with any necessary supportive care and
follow-up secondary prophylaxis to prevent recurrence
• HIV: provide assessment of current HIV management and provide comprehensive plan
to optimize management and reduce future complications/adverse events risk
2. Please provide assessment and plan on secondary problems
3. Please review patient’s course of hospitalization and previous visits (including
appropriateness of medications initiated, monitoring during hospitalization, or any necessary
follow-ups) to assist in responding to the discussion questions
Disclaimer:
• Dovato is ordered as 2 different medications in the chart because EHRGo does not have
Dovato in their medication list. But pretend that patient takes the combination
medication.
• In this case, genotypic HIV resistance tests resulted in within a day. But in practice,
please note that the test typically takes 2-3 weeks.

Discussion Questions
1. (a) Do you agree with the empiric therapy (vancomycin & ceftriaxone) initiated for the
suspected bacterial meningitis? Why or why not? If not, what would you have recommend?
Please assess dosing as well on top of choice of therapy.
(b) Do you agree with the dosing for vancomycin and ceftriaxone? If not, what would be your
recommendation? Please use AUC-based monitoring for vancomycin.
(c) How do you determine duration of therapy for bacterial meningitis?

2. (a) Acyclovir may sometimes be initiated in patients with meningitis if there is a concern for
viral involvement. Do you agree with the acyclovir dose ordered for Megan? Why or why
not? If not, what would be your recommended dose?
(b) Is Megan at risk for acyclovir-induced nephrotoxicity? What risk factors she has?
(c) What are ways to reduce risk for nephrotoxicity if Megan needs to continue treatment
with acyclovir?

3. (a) What primary prophylaxis for other opportunistic infections are indicated for Megan?
(b) Do you agree with the initial antiretroviral therapy (Dovato) started for Megan? Why or
why not? What other alternative did Megan has for initial HIV antiretroviral therapy (discuss
why the alternative will or will not be appropriate for Megan based on patient preference,
insurance coverage, and other necessary patient factors)?

4. (a) The provider initiated insulin glargine on admission due to insulin NPH being nonformulary. Do you agree with the dosing? If not, what would you do differently?
(b) Please provide assessment of T2DM and provide potential plan for discharge/outpatient
management.
(c) What is your assessment and therapeutic plan to manage hypertension while inpatient?

5. (a) Is Megan up-to-date on her vaccinations? If not, what would you recommend for her and
when to administer?
(b) Which vaccines (list at least 3) are contraindicated for her and why? Are there any
exception to any of the contraindicated vaccines?

